o Dupilumab (Dupixent) is an antibody to the IL-4 alpha receptor and decreases pro-inflammatory cytokines. It is approved for use in infants and children 6 months and older. It effectively decreases symptoms after 1 to 2 months of use and shows increases in effectiveness as duration of treatment increases. It has an excellent safety profile, although long-term–use (> 3 years) safety studies are limited. Nasopharyngitis is the most common side effect. Dupilumab is administered as a subcutaneous injection and may be combined with topical corticosteroid, TCI, and phototherapy. (Note that immunization with live or attenuated virus is contraindicated in children just before or during treatment with dupilumab.) Dosing and frequency are weight based in the pediatric population., The most serious infections (eg, eczema herpeticum) may require hospitalization and treatment with systemic medications. Any child with atopic dermatitis should not share eating utensils, toothbrushes, drinking glasses, or other personal items with someone who has a cold sore (herpes simplex virus [HSV] 1 infection)., There are many OTC products available that may help prevent and control eczema symptoms in your child. Visit our directory of over-the-counter products that have received the National Eczema Association Seal of Acceptance™ to find a treatment that works for your child. Prescription treatments Topical medications.